Drug combo safety check: early study completed
NCT ID NCT06717100
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This completed Phase 1 trial studied how deupirfenidone (LYT-100) and nintedanib interact in 24 healthy adults aged 18-65. Participants took both drugs over several weeks to measure drug levels and check for side effects. The goal was to understand potential drug-drug interactions, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- deupirfenidone (LYT-100) and nintedanib
- What this could lead to
- If successful, this study could help determine safe dosing when combining these two drugs for future treatments.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. Results may not predict real-world effects or safety in people with disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG INTERACTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd (Commercial Rd and St Kilda Rd) - VIC
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New shot may lower heart risk in patients whose medications block statins
- New Decision-Making tool aims to prevent bleeding in blood thinner users
- Heart Patients' hidden danger: risky drug mixes under the microscope
- Xanax and opioids: new study tests safety and abuse risk
- Grapefruit juice could change how depression drug works
- Can a simple online survey unlock the secrets to active longevity?